Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponatinib - Incyte Corporation/Otsuka Pharmaceutical/Takeda

Drug Profile

Ponatinib - Incyte Corporation/Otsuka Pharmaceutical/Takeda

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer Fundacion CRIS de Investigacion para Vencer el Cancer; Incyte Biosciences International; Incyte Corporation; Otsuka Beijing Research Institute; Otsuka Pharmaceutical; Takeda; University of Birmingham
  • Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Solid tumours
  • Discontinued Gastrointestinal stromal tumours

Most Recent Events

  • 25 Apr 2025 Takeda completes the phase II OPTIC trial in Chronic myeloid leukaemia (Second-line therapy or greater) in Argentina, Australia, Belgium, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Italy, Poland, Portugal, South Korea, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, US, UK (NCT02467270)
  • 15 Jan 2025 Takeda terminates a phase-I/II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (In adults, In children, In infants, In adolescents, Second-line therapy or greater) in United Kingdom, in the US, Argentina, Australia, Brazil, China, Czech Republic, France, Italy, South Korea, Mexico, Spain, Poland, Portugal and the Netherlands (PO) due to dose-limiting toxicities (NCT04501614) (EudraCT2019-002549-39)
  • 03 Dec 2024 The FDA label for ponatinib carries a black box warning concerning incidences of vascular occlusion, venous thromboembolism, heart failure and hepatotoxicity with its use

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top